Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611286 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL3799467 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10494110 | 0.98 | FOLH1 (0.52) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10494109 | 0.98 | FOLH1 (0.52) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Trifluoroacetic Acid SCHEMBL29695528 | 0.92 | ACE (0.53) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10537166 | 0.91 | FOLH1 (0.47) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL9052244 | 0.86 | FOLH1 (0.43) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL697901 | 0.86 | EPHX1 (0.61) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL697900 | 0.86 | EPHX1 (0.61) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL8211678 | 0.86 | EPHX1 (0.61) | FOLH1NAALAD2MMEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118883955-A | Alzheimer's disease biomarker and application thereof in early diagnosis | 南方医科大学珠江医院 | 2024-11-01 | — | — | CN | claimed |
| CN-114796048-A | Preparation and application of traditional Chinese medicine extract for preparing antioxidant | 宿迁市中医院 | 2022-07-29 | — | — | CN | claimed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | claimed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | claimed |
| EP-1621546-B1 | Peptide ligands specific to immonoglobulins | TECNOGEN SPA (IT) | 2008-10-29 | — | — | EP | claimed |
| CN-101160525-A | Genetic code increase of non-natural active amino acid | SCRIPPS RESEARCH INST (US) | 2008-04-09 | — | — | CN | claimed |
| EP-1621546-A1 | Peptide ligands specific to immonoglobulins | TECNOGEN S.C.P.A. (IT) | 2006-02-01 | — | — | EP | claimed |
| US-20040261198-A1 | Restructuring and finishing of keratin fibers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2004-12-30 | — | — | US | claimed |
| CN-1031051-C | Cycloalkyl-substituted glutaramide antihypertensive agents | PFIZER (US) | 1996-02-21 | — | — | CN | claimed |
| US-5122461-A | Reacting monophenolic compounds with oxygen in presence of monophenol monooxygenase and metal ions; product stabilized by complexing with metals; increasing DOPA yield | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1992-06-16 | — | — | US | claimed |
| US-4789757-A | N-formylation of amino carboxylic compounds with formamide | W. R. GRACE & CO.-CONN. (US) | 1988-12-06 | — | — | US | claimed |
| JP-57058626-A | — | — | None | — | — | JP | disclosed |
| WO-2025049431-A2 | CONTROL OF FLUX TOWARD 2-PHENYLETHANOL PRODUCTION | INSCRIPTA, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119331778-A | Lactic acid bacteria composition for adjuvant treatment of diabetes and composite lactic acid bacteria probiotic and application thereof | 均瑶润盈生物科技(上海)有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-118883955-A | Alzheimer's disease biomarker and application thereof in early diagnosis | 南方医科大学珠江医院 | 2024-11-01 | — | — | CN | disclosed |
| WO-1999024604-A1 | METHOD AND AGENT FOR DETERMINING AN ENZYMATIC ACTIVITY SUCH AS DEAMINASE | BIO MERIEUX (FR) | 1999-05-20 | — | — | WO | disclosed |
| US-5122461-A | Reacting monophenolic compounds with oxygen in presence of monophenol monooxygenase and metal ions; product stabilized by complexing with metals; increasing DOPA yield | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1992-06-16 | — | — | US | disclosed |
| US-4801742-A | N-formylation of amino carboxylates with alkyl formates | W. R. GRACE & CO.-CONN. (US) | 1989-01-31 | — | — | US | disclosed |
| JP-S5758626-A | CARCINOSTATIC AGENT | RIKAGAKU KENKYUSHO | 1982-04-08 | — | — | JP | disclosed |
| US-4171225-A | HYDROXYMETHYL AMINO ALKYLCARBOXYLIC OR -SULFONIC ACID ALKALI SALTS AS STABLE REDUCING AGENTS | U.S. PHILIPS CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | FOLH1 723/4885NAALAD2 1944/4885SLC7A5 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.